Last reviewed · How we verify

Biliary Obstruction with Pruritus — Treatment Landscape & Competitive Intelligence

Biliary Obstruction with Pruritus (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Biliary Obstruction with Pruritus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Questran Light CHOLESTYRAMINE Bristol Myers Bile Acid Sequestrant [EPC] 1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol Myers · 1 drug in Biliary Obstruction with Pruritus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Biliary Obstruction with Pruritus:

Cite this brief

Drug Landscape (2026). Biliary Obstruction with Pruritus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/biliary-obstruction-with-pruritus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing